Open-label, multicenter phase IV study of ribavirin (Copegus) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients with chronic hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2015
At a glance
- Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ANECO
- Sponsors Roche
- 26 Apr 2014 New source identified and integrated (EudraCT: 2011-001256-10)
- 31 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Aug 2013 Planned End Date changed from 1 Jul 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.